A Population Pharmacokinetic Model-Guided Evaluation of Ceftolozane-Tazobactam Dosing in Critically Ill Patients Undergoing Continuous Venovenous Hemodiafiltration

被引:26
|
作者
Sime, Fekade B. [1 ,2 ]
Lassig-Smith, Melissa [3 ]
Starr, Therese [3 ]
Stuart, Janine [3 ]
Pandey, Saurabh [1 ]
Parker, Suzanne L. [1 ]
Wallis, Steven C. [1 ]
Lipman, Jeffrey [1 ,3 ,4 ]
Roberts, Jason A. [1 ,2 ,3 ,4 ,5 ]
机构
[1] Univ Queensland, Ctr Clin Res, Fac Med, Brisbane, Qld, Australia
[2] Univ Queensland, Ctr Translat Antiinfect Pharmacodynam, Sch Pharm, Brisbane, Qld, Australia
[3] Royal Brisbane & Womens Hosp, Dept Intens Care Med, Brisbane, Qld, Australia
[4] Univ Montpellier, Nimes Univ Hosp, Div Anaesthesiol Crit Care Emergency & Pain Med, Nimes, France
[5] Royal Brisbane & Womens Hosp, Pharm Dept, Brisbane, Qld, Australia
基金
英国医学研究理事会;
关键词
ceftolozane-tazobactam; pharmacokinetics; renal replacement therapy; hemodiafiltration; CRRT; RENAL REPLACEMENT THERAPY; PSEUDOMONAS-AERUGINOSA; CLEARANCE;
D O I
10.1128/AAC.01655-19
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The aim of this work was to describe optimized dosing regimens of ceftolozane-tazobactam for critically ill patients receiving continuous venovenous hemodiafiltration (CVVHDF). We conducted a prospective observational pharmacokinetic study in adult critically ill patients with clinical indications for ceftolozane-tazobactam and CVVHDF. Unbound drug concentrations were measured from serial prefilter blood, postfilter blood, and ultrafiltrate samples by a chromatographic assay. Population pharmacokinetic modeling and dosing simulations were performed using Pmetrics. A four-compartment pharmacokinetic model adequately described the data from six patients. The mean (+/- standard deviation [SD]) extraction ratios for ceftolozane and tazobactam were 0.76 +/- 0.08 and 0.73 +/- 0.1, respectively. The mean +/- SD sieving coefficients were 0.94 +/- 0.24 and 1.08 +/- 0.30, respectively. Model-estimated CVVHDF clearance rates were 2.7 +/- 0.8 and 3.0 +/- 0.6 liters/h, respectively. Residual non-CVVHDF clearance rates were 0.6 +/- 0.5 and 3.3 +/- 0.9 liters/h, respectively. In the initial 24 h, doses as low as 0.75 g every 8 h enabled cumulative fractional response of >= 85% for empirical coverage against Pseudomonas aeruginosa, considering a 40% fT (>MIC) (percentage of time the free drug concentration was above the MIC) target. For 100% fT (>MIC), doses of at least 1.5 g every 8 h were required. The median (interquartile range) steady-state trough ceftolozane concentrations for simulated regimens of 1.5 g and 3.0 g every 8 h were 28 (21 to 42) and 56 (42 to 84) mg/liter, respectively. The corresponding tazobactam concentrations were 6.1 (5.5 to 6.7) and 12.1 (11.0 to 13.4) mg/liter, respectively. We suggest a front-loaded regimen with a single 3.0-g loading dose followed by 0.75 g every 8 h for critically ill patients undergoing CVVHDF with study blood and dialysate flow rates.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Optimizing ceftolozane-tazobactam dosage in critically ill patients during continuous venovenous hemodiafiltration
    Gerardo Aguilar
    Rafael Ferriols
    Sara Martínez-Castro
    Carlos Ezquer
    Ernesto Pastor
    José A. Carbonell
    Manuel Alós
    David Navarro
    Critical Care, 23
  • [2] Optimizing ceftolozane-tazobactam dosage in critically ill patients during continuous venovenous hemodiafiltration
    Aguilar, Gerardo
    Ferriols, Rafael
    Martinez-Castro, Sara
    Ezquer, Carlos
    Pastor, Ernesto
    Carbonell, Jose A.
    Alos, Manuel
    Navarro, David
    CRITICAL CARE, 2019, 23 (1):
  • [3] Population pharmacokinetic/pharmacodynamic evaluations of amikacin dosing in critically ill patients undergoing continuous venovenous hemodiafiltration
    Li, Sanwang
    Zhu, Sucui
    Xie, Feifan
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2023, 75 (04) : 515 - 522
  • [4] Ceftolozane-Tazobactam Pharmacokinetics in a Critically Ill Patient on Continuous Venovenous Hemofiltration
    Oliver, Wesley D.
    Heil, Emily L.
    Gonzales, Jeffrey P.
    Mehrotra, Shailly
    Robinett, Kathryn
    Saleeb, Paul
    Nicolau, David P.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (03) : 1899 - 1901
  • [5] A Loading Micafungin Dose in Critically Ill Patients Undergoing Continuous Venovenous Hemofiltration or Continuous Venovenous Hemodiafiltration: A Population Pharmacokinetic Analysis
    Garbez, Nicolas
    Mbatchi, Litaty C.
    Maseda, Emilio
    Luque, Sonia
    Grau, Santiago
    Wallis, Steven C.
    Muller, Laurent
    Lipman, Jeffrey
    Roberts, Jason A.
    Lefrant, Jean-Yves
    Roger, Claire
    THERAPEUTIC DRUG MONITORING, 2021, 43 (06) : 747 - 755
  • [6] Pharmacokinetic-Pharmacodynamic- Model-Guided Doripenem Dosing in Critically Ill Patients
    Samtani, Mahesh N.
    Flamm, Robert
    Kaniga, Kone
    Nandy, Partha
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (06) : 2360 - 2364
  • [7] Population pharmacokinetic model-guided optimization of intravenous voriconazole dosing regimens in critically ill patients with liver dysfunction
    Lin, Xiao-bin
    Lui, Ka Yin
    Guo, Peng-hao
    Liu, Xiao-man
    Liang, Tao
    Hu, Xiao-guang
    Tong, Li
    Wu, Jing-jing
    Xia, Yan-zhe
    Chen, Pan
    Zhong, Guo-ping
    Chen, Xiao
    Cai, Chang-jie
    PHARMACOTHERAPY, 2022, 42 (01): : 23 - 33
  • [8] Pharmacokinetic Evaluation of Voriconazole Treatment in Critically Ill Patients Undergoing Continuous Venovenous Hemofiltration
    Radej, Jaroslav
    Krouzecky, Ales
    Stehlik, Pavel
    Sykora, Roman
    Chvojka, Jiri
    Karvunidis, Thomas
    Novak, Ivan
    Matejovic, Martin
    THERAPEUTIC DRUG MONITORING, 2011, 33 (04) : 393 - 397
  • [9] A Loading Micafungin Dose in Critically Ill Patients Undergoing Continuous Venovenous Hemofiltration or Continuous Venovenous Hemodiafiltration: A Population Pharmacokinetic Analysis (vol 43, pg 747, 2021)
    Garbez, N.
    Mbatchi, L. C.
    Maseda, E.
    THERAPEUTIC DRUG MONITORING, 2022, 44 (02) : 357 - 357
  • [10] Pharmacokinetics and drug dosing adjustments during continuous venovenous hemofiltration or hemodiafiltration in critically ill patients
    Bugge, JF
    ACTA ANAESTHESIOLOGICA SCANDINAVICA, 2001, 45 (08) : 929 - 934